

Evaluation of the role of Lymphadenectomy In high-risk Prostate cancer SurgEry

Submission date 02/08/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 06/08/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 06/10/2025	Condition category Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Every year in the UK, nearly 50,000 people are diagnosed with prostate cancer and over 10,000 men die from it. Prostate cancer that has not spread elsewhere in the body but is at risk of doing so is referred to as high-risk localised prostate cancer. Established treatment options for high-risk prostate cancer are surgery and radiotherapy. In the UK, 4000 patients a year undergo surgery for high-risk prostate cancer. When surgeons operate on men with high-risk prostate cancer, they remove the entire prostate gland and, in some cases, also remove the nearby lymph nodes (an immune tissue that forms the early landing sites for cancer spread) in a surgery called pelvic lymph node dissection (PLND). It is thought that PLND gives better cancer clearance and reduces recurrence, which is seen in 30-50% of men with high-risk disease. However, complications can arise from PLND. These complications may reduce the quality of life, and along with the increased surgical time required, lymph node surgery in addition to removing the prostate might result in additional costs to the NHS. The study team surveyed UK surgeons and found variable practice with 35% of eligible patients getting lymph node excision. Surgeons stated that the current evidence was not good enough to inform decisions about whether it was beneficial to do a lymph node excision knowing that there are potential harms, and a clinical trial comparing lymph node excision to no lymph node excision was urgently required. This clinical trial aims to compare the two treatments in terms of their effect over 3 years on, prostate cancer recurrence, quality of life, complication rates, survival and use of NHS resources. Everyone who takes part will have an equal chance of either having their lymph nodes removed or not during their prostate cancer PCa surgery. The study will recruit 1080 patients from 25 hospitals across the UK.

Who can participate?

Adults aged 18 years old and over with biopsy-proven clinically localised high-risk prostate cancer who are suitable for radical prostatectomy

What does the study involve?

Adults who consent to participate in ELIPSE will be randomly allocated to one of the two types of surgery mentioned above. After the surgery, they will be sent participants questionnaires for

up to 36 months to collect information on several things, including cancer recurrence, harms, quality of life, time to return to normal activities, and costs. Further information will also be collected from their routine follow-up that is recorded in their medical records.

What are the possible benefits and risks of participating?

Participants may not benefit personally from taking part but, by taking part, will help inform the treatment of future patients who need to have radical prostatectomy. The results of the ELIPSE study will help doctors, surgeons, patients and health services decision-makers understand whether it is better to remove lymph nodes during a radical prostatectomy, or not. Both types of surgery are already being used in the NHS to treat patients. There are risks associated with all surgical procedures but there should be no additional risk in taking part in the study.

Where is the study run from?

The Cardiff and Vale University Health Board are leading the study. The day-to-day management of the study is being led by the University of Aberdeen. Hospital sites across the UK will take part.

When is the study starting and how long is it expected to run for?

February 2024 to August 2029

Who is funding the study?

The National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme

Who is the main contact?

Maria Ntessalen, elipse@abdn.ac.uk

Contact information

Type(s)

Principal investigator

Contact name

Dr Krishna Narahari

ORCID ID

<https://orcid.org/0000-0003-0257-7033>

Contact details

Urology Department, Cardiff and Vale University Health Board, Heath Park Way
Cardiff

United Kingdom

CF14 4XW

+44 02920743318

krishna.narahari@wales.nhs.uk

Type(s)

Principal investigator

Contact name

Prof Rakesh Heer

ORCID ID

<https://orcid.org/0000-0003-1952-7462>

Contact details

Division of Surgery, Imperial College London, Hammersmith House, Hammersmith Campus
London

United Kingdom

W12 0NN

-

r.heer@imperial.ac.uk

Type(s)

Public

Contact name

Ms Maria Ntessalen

ORCID ID

<https://orcid.org/0000-0002-8178-8666>

Contact details

Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen
Aberdeen

United Kingdom

AB25 2ZD

+44 (0)1224 437263

elipse@abdn.ac.uk

Type(s)

Public

Contact name

Ms Seonaidh Cotton

ORCID ID

<https://orcid.org/0000-0002-7883-0608>

Contact details

Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen
Aberdeen

United Kingdom

AB25 2ZD

+44 (0)1224 438178

s.c.cotton@abdn.ac.uk

Additional identifiers**Clinical Trials Information System (CTIS)**

Nil known

Integrated Research Application System (IRAS)

329888

Protocol serial number

CPMS 63289, IRAS 329888, NIHR152686

Study information

Scientific Title

A randomised controlled trial comparing the clinical and cost-effectiveness of lymph node removal in patients undergoing curative surgery for localised high-risk prostate cancer

Acronym

ELIPSE

Study objectives

Radical prostatectomy plus pelvic lymph node dissection offers better cancer control than radical prostatectomy alone in patients undergoing surgery for high-risk prostate cancer.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 04/07/2024, West of Scotland REC 5 (NHS Greater Glasgow & Clyde, West of Scotland Research Ethics Service, Ward 11, Dykebar Hospital, Grahamston Road, Paisley, PA2 7DE, United Kingdom; +44 (0)141 314 0213; WoSREC5@ggc.scot.nhs.uk), ref: 24/WS/0075

Study design

Randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Biopsy-proven clinically localised high-risk prostate cancer

Interventions

Participants will be identified through screening in local and regional specialist multi-disciplinary teams. Adult males with biopsy-proven clinically localised high-risk PCa, where the local multi-disciplinary review has identified them as suitable for radical prostatectomy, with negative staging imaging and who are able and willing to give informed consent and participate in study procedures will be considered for inclusion. Potential participants who have had hormone therapy within the 3 months before consent will be excluded from the study.

Eligible patients will be provided with a Participant Information Leaflet (PIL) containing information about the study. If interested the patient will have the opportunity to discuss the surgical options and ask any questions about the study with a member of the clinical team,

either face-to-face or virtually. Eligible patients can discuss the study with other NHS team members, their GP, as well as family and friends before deciding whether to participate in the trial. If the participant decides to give their consent, they will be asked to sign a consent form either during a hospital visit or at home (and return through the post).

Participants will be asked to complete a baseline questionnaire which asks about their generic and prostate-cancer-specific quality of life. Where consent is by post, this may be completed at the same time and posted back with the consent. The local research team will complete a baseline case report form collecting data on age, sex assigned at birth, ethnicity, height, weight, postcode, medical history, smoking status, Gleason grade and stage. The results of the prostate-specific antigen (PSA) test considered by the MDT will also be recorded.

Participants will be randomised as close to the time of surgery as is feasible to receive either radical prostatectomy (RP) with pelvic lymph node dissection (PLND) or radical prostatectomy alone. The procedure will be undertaken as per standard NHS care. Blinding of surgeons is not possible and participants will be informed of their treatment allocation.

The local research team will collect information about the surgical procedure, any intraoperative complications and pathology results from medical records (or in real-time, as applicable).

The date and results of all post-surgery PSA tests up to 3 years will be recorded by the research team from laboratory records.

3 months after surgery, the local research team will collect information from the medical records to complete the Comprehensive Complications Index, recording any complications following surgery.

At 36 months post-surgery the local research team will review the participant's medical notes to identify any further related use of NHS resources, recurrence from routine scans and absence of demonstrable metastasis.

Participants will also be asked to complete questionnaires by post, email or text (as per participant preference) at 3 months after surgery and 12, 24 and 36 months after surgery to collect information (at the relevant time point) on quality of life, quality of recovery, NHS resource use and participant costs, time and travel and to report any complications and further treatments. Around 36 months, the team at the site will also contact the participants by phone to find out if they had any additional visits to hospitals that the local team was not aware of.

Outcomes will be compared between radical prostatectomy (RP) with pelvic lymph node dissection (PLND) or radical prostatectomy alone.

Participants are free to withdraw consent from the study at any time point.

Intervention Type

Procedure/Surgery

Primary outcome(s)

1. Cancer recurrence, defined as prostate-specific antigen (PSA) recurrence/persistence with two consecutive measures ≥ 0.2 ng/ml and/or disease progression (eg metastatic disease) and/or need for further prostate cancer treatment and/or prostate cancer-specific death and is assessed over 3 years.
2. Economic outcome measured as incremental cost per QALY gained at 3 years

Key secondary outcome(s)

1. Harms (complications and re-intervention rates) measured using CLASSIntra during surgery, the Comprehensive Complications Index at 3 months, from medical records up to 3 years, and questionnaires at 12, 24 and 36 months
2. Complete excision of the primary prostate tumour measured using the surgical margins after surgery
3. Metastasis-free survival measured using imaging from routine follow-up
4. Health-related quality of life measured using EPIC 26 and EQ-5D-5L questionnaires at baseline, and 3, 12, 18, 24 and 36 months
5. Time to return to normal activities measured using a questionnaire at 3 months
6. Indirect costs due to productivity losses measured using a questionnaire at 12, 24 and 26 months
7. Costs to participants measured using a questionnaire at 12, 24 and 36 months

Completion date

31/08/2029

Eligibility

Key inclusion criteria

1. Adults ≥ 18 years
2. Biopsy-proven clinically localised high-risk PCa
3. Local multi-disciplinary review identifying those cases thought be suitable for RP; with negative staging imaging (as per local standard of care)
4. Able and willing to give informed consent to participate and to participate in study procedures

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Male

Key exclusion criteria

1. Hormone therapy within the 3 months prior to consent
2. Previous radical treatment for PCa (radical treatment includes radical prostatectomy and/or radiotherapy and/or focal therapy [eg cryotherapy or HIFU])
3. Unsuitable for surgical treatment
4. People without capacity

Date of first enrolment

01/09/2024

Date of final enrolment

31/08/2026

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre

Cardiff & Vale University Lhb

Woodland House

Maes-y-coed Road

Cardiff

United Kingdom

CF14 4HH

Study participating centre

Royal Liverpool University Hospital

Prescot Street

Liverpool

United Kingdom

L7 8XP

Study participating centre

Gartnavel Royal Hospital

1055 Great Western Road

Glasgow

United Kingdom

G12 0XH

Study participating centre

St James University Hospital NHS Trust

St James's University Hospital

Gledow Wing

Beckett Street

Leeds
United Kingdom
LS9 7TF

Study participating centre
Aberdeen Royal Infirmary
Foresterhill Road
Aberdeen
United Kingdom
AB25 2ZN

Study participating centre
University Hospital (coventry)
Clifford Bridge Road
Coventry
United Kingdom
CV2 2DX

Study participating centre
Guy's and St Thomas' NHS Foundation Trust
St Thomas' Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH

Study participating centre
Charing Cross Hospital
Fulham Palace Road
London
United Kingdom
W6 8RF

Study participating centre
Darent Valley Hospital
Darenth Wood Road
Dartford
United Kingdom
DA2 8AA

Study participating centre
Lincoln County Hospital Laboratory
Lincoln County Hospital
Greetwell Road
Lincoln
United Kingdom
LN2 5QY

Study participating centre
Royal Hallamshire Hospital
Glossop Road
Sheffield
United Kingdom
S10 2JF

Study participating centre
Nottingham University Hospitals NHS Trust - City Campus
Nottingham City Hospital
Hucknall Road
Nottingham
United Kingdom
NG5 1PB

Study participating centre
North Bristol NHS Trust
Southmead Hospital
Southmead Road
Westbury-on-trym
Bristol
United Kingdom
BS10 5NB

Study participating centre
University College London Hospitals NHS Foundation Trust
250 Euston Road
London
United Kingdom
NW1 2PG

Study participating centre

Lister Hospital
Coreys Mill Lane
Stevenage
United Kingdom
SG1 4AB

Study participating centre
Sunderland Royal Hospital
Kayll Road
Sunderland
United Kingdom
SR4 7TP

Study participating centre
Norfolk & Norwich University Hospital
Colney Lane
Colney
Norwich
United Kingdom
NR4 7UY

Study participating centre
Leicester General Hospital
Gwendolen Road
Leicester
United Kingdom
LE5 4PW

Study participating centre
New Cross Hospital Royal Wolverhampton
Wolverhampton Road
Heath Town
Wolverhampton
United Kingdom
WV10 0QP

Study participating centre
Addenbrookes
Addenbrookes Hospital
Hills Road
Cambridge

United Kingdom
CB2 0QQ

Study participating centre

The Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle upon Tyne
United Kingdom
NE7 7DN

Study participating centre

Swansea Bay Cds
One Talbot Gateway
Baglan Energy Park
Port Talbot
United Kingdom
SA12 7BR

Study participating centre

Mid Yorkshire Teaching NHS Trust
Pinderfields Hospital
Aberford Road
Wakefield
United Kingdom
WF1 4DG

Study participating centre

The Christie
550 Wilmslow Road
Withington
Manchester
United Kingdom
M20 4BX

Study participating centre

Royal Surrey County Hospital
Egerton Road

Guildford
United Kingdom
GU2 7XX

Study participating centre
Royal Devon & Exeter Foundation Hospital
Barrack Road
Exeter
United Kingdom
EX2 5DW

Study participating centre
Cheltenham General Hospital
Sandford Road
Cheltenham
United Kingdom
GL53 7AN

Study participating centre
University Hospital Monklands
Monkscourt Avenue
Airdrie
United Kingdom
ML6 0JS

Study participating centre
Southend University Hospital
Prittlewell Chase
Westcliff-on-sea
United Kingdom
SS0 0RY

Study participating centre
Clatterbridge Cancer Centre
Clatterbridge Hospital
Clatterbridge Road
Wirral
United Kingdom
CH63 4JY

Study participating centre**Royal Berkshire Hospital**

London Road
Reading
United Kingdom
RG1 5AN

Study participating centre**Southampton General Hospital**

Tremona Road
Southampton
United Kingdom
SO16 6YD

Study participating centre**NIHR St George's Clinical Research Facility**

St George's, University of London
Cranmer Terrace
London
London
United Kingdom
SW17 0RE

Sponsor information

Organisation

Cardiff and Vale University Health Board

ROR

<https://ror.org/0489f6q08>

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file	version 3	05/07/2024	05/08/2024	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes